Literature DB >> 16622274

Aromatase inhibitor withdrawal response in metastatic breast cancer.

Tessa Cigler1, Paul E Goss.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16622274     DOI: 10.1200/JCO.2005.03.4108

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

Authors:  Xiaonan Hou; Fei Huang; Luciana F Macedo; Sean C Harrington; Karen A Reeves; Ann Greer; Friedrich Graf Finckenstein; Angela Brodie; Marco M Gottardis; Joan M Carboni; Paul Haluska
Journal:  Cancer Res       Date:  2011-10-31       Impact factor: 12.701

2.  Endocrine-responsive breast cancer: a 28-year Odyssey.

Authors:  A West; Kp Friedman; F Muggia
Journal:  Ecancermedicalscience       Date:  2011-12-01

3.  Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy.

Authors:  Y Chavarri-Guerra; M J Higgins; J Szymonifka; T Cigler; P Liedke; A Partridge; J Ligibel; S E Come; D Finkelstein; P D Ryan; P E Goss
Journal:  Br J Cancer       Date:  2014-09-18       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.